{"id":"melphalan-prednisone-lenalidomide","safety":{"commonSideEffects":[{"rate":"20-50%","effect":"Nausea"},{"rate":"10-30%","effect":"Vomiting"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Fatigue"},{"rate":"5-15%","effect":"Anemia"},{"rate":"5-10%","effect":"Thrombocytopenia"},{"rate":"5-10%","effect":"Neutropenia"},{"rate":"5-10%","effect":"Infection"},{"rate":"5-10%","effect":"Hypertension"},{"rate":"5-10%","effect":"Hyperglycemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Melphalan works by attaching to DNA and interfering with its replication, leading to cell death. Prednisone suppresses the immune system by inhibiting the production of inflammatory cytokines. Lenalidomide affects cell growth and survival by modulating the activity of various signaling pathways.","oneSentence":"Melphalan is an alkylating agent that interferes with DNA replication, Prednisone is a corticosteroid that suppresses the immune system, Lenalidomide is an immunomodulatory drug that affects cell growth and survival.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:20:38.786Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma"},{"name":"Hodgkin lymphoma"}]},"trialDetails":[{"nctId":"NCT00602641","phase":"PHASE3","title":"Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2008-02-29","conditions":"Multiple Myeloma","enrollment":306},{"nctId":"NCT01208766","phase":"PHASE3","title":"Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma","status":"COMPLETED","sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","startDate":"2011-01","conditions":"Multiple Myeloma","enrollment":1503},{"nctId":"NCT03829371","phase":"PHASE4","title":"STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Turin, Italy","startDate":"2019-01-03","conditions":"Multiple Myeloma","enrollment":450},{"nctId":"NCT03412565","phase":"PHASE2","title":"A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-04-26","conditions":"Multiple Myeloma","enrollment":265},{"nctId":"NCT01998971","phase":"PHASE1","title":"A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-02-18","conditions":"Multiple Myeloma","enrollment":240},{"nctId":"NCT01093196","phase":"PHASE3","title":"Lenalidomide and Dexamethasone Versus Melphalan Prednisone and Lenalidomide Versus Cyclophosphamide, Prednisone and Lenalidomide in Elderly Multiple Myeloma Patients","status":"COMPLETED","sponsor":"Fondazione EMN Italy Onlus","startDate":"2009-10","conditions":"Multiple Myeloma","enrollment":660},{"nctId":"NCT00551928","phase":"PHASE3","title":"Lenalidomide Melphalan and Prednisone Versus High Dose Melphalan in Newly Diagnosed Multiple Myeloma Patients","status":"COMPLETED","sponsor":"Fondazione EMN Italy Onlus","startDate":"2007-06","conditions":"Multiple Myeloma, Newly Diagnosed Patients","enrollment":402},{"nctId":"NCT02206425","phase":"PHASE1, PHASE2","title":"Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients","status":"COMPLETED","sponsor":"Oncotherapeutics","startDate":"2014-09","conditions":"Multiple Myeloma","enrollment":45},{"nctId":"NCT01160107","phase":"PHASE2","title":"Revlimid And Prednisone Followed By Revlimid, Melphalan And Prednisone In Multiple Myeloma Patients","status":"COMPLETED","sponsor":"Fondazione EMN Italy Onlus","startDate":"2008-07","conditions":"Multiple Myeloma","enrollment":46},{"nctId":"NCT03742297","phase":"PHASE3","title":"Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years","status":"ACTIVE_NOT_RECRUITING","sponsor":"PETHEMA Foundation","startDate":"2018-10-22","conditions":"Newly Diagnosed Multiple Myeloma","enrollment":462},{"nctId":"NCT02112175","phase":"PHASE3","title":"Lenalidomide vs Placebo Maintenance Therapy Following Melphalan Prednisone Velcade® Induction Therapy in NDMM","status":"COMPLETED","sponsor":"Celgene","startDate":"2014-04-30","conditions":"Multiple Myeloma","enrollment":46},{"nctId":"NCT00907452","phase":"NA","title":"Pharmacogenomic Study in Myeloma Patients Treated With Melphalan-prednisone-thalidomide or Lenalidomide-dexamethasone","status":"COMPLETED","sponsor":"Intergroupe Francophone du Myelome","startDate":"2009-07-29","conditions":"Myeloma","enrollment":143},{"nctId":"NCT00689936","phase":"PHASE3","title":"Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma","status":"COMPLETED","sponsor":"Celgene","startDate":"2008-08-21","conditions":"Multiple Myeloma","enrollment":1623},{"nctId":"NCT00477750","phase":"PHASE1, PHASE2","title":"Melphalan, Prednisone, and Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2005-06","conditions":"Multiple Myeloma and Plasma Cell Neoplasm","enrollment":33},{"nctId":"NCT02145598","phase":"PHASE2, PHASE3","title":"Treatment Optimization in Patients With Untreated Multiple Myeloma","status":"TERMINATED","sponsor":"Dr. med. Lars-Olof Muegge","startDate":"2013-08","conditions":"Multiple Myeloma","enrollment":85},{"nctId":"NCT01237249","phase":"PHASE2","title":"Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"2011-02","conditions":"Multiple Myeloma","enrollment":250},{"nctId":"NCT00405756","phase":"PHASE3","title":"A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older.","status":"COMPLETED","sponsor":"Celgene Corporation","startDate":"2007-01","conditions":"Newly Diagnosed Multiple Myeloma","enrollment":459},{"nctId":"NCT00961467","phase":"PHASE2","title":"RMPT for Relapsed/Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Fondazione EMN Italy Onlus","startDate":"2007-02","conditions":"Multiple Myeloma","enrollment":44},{"nctId":"NCT00691704","phase":"PHASE2","title":"Celgene High Risk Multiple Myeloma (MM) Revlimid Induction and Maintenance Therapy","status":"COMPLETED","sponsor":"Cristina Gasparetto","startDate":"2008-08","conditions":"Multiple Myeloma","enrollment":18},{"nctId":"NCT00396045","phase":"PHASE1, PHASE2","title":"Melphalan, Prednisone, and CC-5013 (Revlimid) as Induction Therapy in Multiple Myeloma","status":"COMPLETED","sponsor":"University of Turin, Italy","startDate":"2005-01","conditions":"Multiple Myeloma","enrollment":54}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":21,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Melphalan, Prednisone, Lenalidomide","genericName":"Melphalan, Prednisone, Lenalidomide","companyName":"Fondazione EMN Italy Onlus","companyId":"fondazione-emn-italy-onlus","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Melphalan is an alkylating agent that interferes with DNA replication, Prednisone is a corticosteroid that suppresses the immune system, Lenalidomide is an immunomodulatory drug that affects cell growth and survival. Used for Multiple myeloma, Hodgkin lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}